



## ASX MARKET ANNOUNCEMENT

### FarmaForce Limited - Contract Update

22<sup>nd</sup> May 2015

iQ3Corp Ltd (ASX:IQ3) is pleased to announce that a previously ratified agreement, which mandated iQ3Corp to act as lead manager, corporate advisor and to capital raise for FarmaForce's pre-Initial Public Offering (IPO), has now been extended to cover the IPO.

More specifically, iQ3 will now be:

- Acting as lead manager and corporate advisor for the IPO
- Conduct the IPO capital raising
- Managing the underwriting of the offer

Our CEO, Dr. George Syrmalis said, "These are great times for Australian companies developing biotechnology or life science products.

"These IP rich enterprises should be proactively planning to list on a high profile stock exchange. The funds they raise will expedite their research and commercialization protocol".

For more information, please feel free to contact the iQ3Corp Investor Relations Team.

Email:

[investor.relations@iq3corp.com](mailto:investor.relations@iq3corp.com)

Phone:

+61 2 8239 5400

#### **About iQ3Corp Limited:**

iQ3Corp is a specialised life science corporate finance and advisory firm bridging capital with science to create the medicines of the future.

#### **Disclaimer**

Subject to any continuing obligations under the laws of the Commonwealth of Australia or the ASX listing rules, iQ3Corp Ltd (iQ3Corp or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements. The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQ3Corp and detailed in this announcement represents the Company's strategic planning and decision-making practices and are based on current expectations. iQ3Corp's business is subject to uncertainties, risks and contingencies, many

iQ3Corp. Ltd  
ABN: 63 160 238 282  
iq3corp.com

Levels 3 & 6  
222 Clarence Street  
Sydney NSW 2000

Tel: +61 2 8239 5400  
Fax: +61 2 8362 9547  
info@iq3corp.com



of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQ3Corp to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQ3Corp's business, its associated risks and operations can be found in its periodic announcements to ASX.